

CANNOID

ENCAPSULATION TECHNOLOGIES

Founded in 2013, Cannoid is the nation's premier contract manufacturer for hemp-based softgels. We have deep roots in the CBD business and we are the production engine behind many prominent consumer-facing brands in the space. Our commitment to innovation and process control make us a high-value partner to industry. We have manageable MOQ's on custom runs, we turn orders in days rather than months, and we keep costs down. Please contact us at 303.514.5148 or info@cannoid.com to request samples and COA's or to discuss the details of your project.

BULK SOFTGELS

Several standard formulations are available for immediate delivery. Made from the finest extracts and isolates, each stock gelcap possesses a complete, natural profile of cannabinoids, terpenoids, and flavonoids to maximize value and therapeutic effect. All stock softgels are available in either MCT or hemp seed oil carrier.

Standard CBD Softgels

- Entourage Full Spectrum: 10mg, 15mg, 20mg and 25mg (0.5ml fill).
- Ultra Broad Spectrum: 25mg (0.5ml fill) and 50mg (0.25ml fill).

Specialty Softgels

- 20mg CBDA + 20mg CBGA (0.5ml fill). *Immune Support, Covid*
- 25mg CBD + 3mg CBN + 3mg Melatonin (0.5ml fill). *Rest*
- 20mg CBD + 5mg CBN (0.5ml fill). *Sleep*
- 20mg CBN + 20mg CBD + 4mg CBDV (0.25ml fill). *Deep Sleep*
- 20mg CBD + 5mg CBG (0.5ml fill). *Recovery*
- 25mg CBD + 10mg Curcumin (0.5ml fill). *Recovery*
- 50mg CBD + 5mg THCv (0.25ml fill). *Appetite, Diabetes*
- 350mg CBD + 9mg CBDV (1ml fill). *Neuromodulation, ASD*
- 15mg Mitragynine Alkaloids (0.5ml fill). *Opioid Replacement*



CUSTOM SOFTGELS

Bring us your actives or pre-formulated oil, or let us formulate to your specifications using our premium raw materials. We maintain a good supply of carrier oil (organic hemp seed oil and MCT) and cannabinoids (extract, distillate, isolate). MOQ is only 50,500 softgels (26L). Typical lead time is only **7 days!**

- #4 Round (0.25ml fill), #8 Oval (0.5ml fill) or #20 Oblong (1.0ml fill).
- Extracts and Isolates: CBD, CBG, CBN, CBDA, CBGA, THCv and CBDV.
- Waxless Suspensions: Terpenes, Melatonin, Curcumin, Mitragynine.
- Any bottle, any size, any fill: HDPE, PET, Glass.
- Pharmaceutical blister packs. Custom-printed foil options.
- Retail-ready display boxes, blister cards, sachets, and premium labels.



303.514.5148
info@cannoid.com
www.cannoid.com





Cannoid, LLC is at the forefront of developing innovative cannabinoid-based therapeutics for new market commercialization and in support of continued clinical and academic research. Literally hundreds of clinical studies are underway involving cannabinoids, and Cannoid has emerged as the trusted partner for creating unit-dose research materials that are tightly controlled for potency and quality. In addition, Cannoid is uniquely positioned to support new product development involving targeted cannabinoid therapeutics.

CANNABIDIOLIC ACID (CBDA) + CANNABIGEROLIC ACID (CBGA)

The raw, acidic cannabinoids CBDA and CBGA are in the news of late due to some compelling anti-Covid properties recently discovered by researchers at Oregon State University¹. According to the investigators, *“Our infection inhibition assay results clearly indicate that CBDA and CBGA are both able to block cell entry by SARS-CoV-2.”*

Cannoid is now distributing 2 versions of our “immunity” softgels to address this new and exciting market opportunity. The **20/20 Immunity softgel** features 20mg each of CBDA and CBGA in a 60mg total load spanning 8 full-spectrum cannabinoids. The **10/10 Immunity softgel** contains a blend of 11 cannabinoids, including 10mg each of CBDA and CBGA. Both softgels are rich in natural, complementary terpenes and flavonoids to maximize therapeutic response, and are guaranteed to be free of residual solvents and other contaminants common in products made from isolated acidic cannabinoids.



(1) van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. *J Nat Prod.* 2022 Jan 28;85(1):176-184. doi: 10.1021/acs.jnatprod.1c00946. Epub 2022 Jan 10. PMID: 35007072; PMCID: PMC8768006. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768006/>



303.514.5148
info@cannoid.com
www.cannoid.com





TETRAHYDROCANNABIVARIN (THCV)

THCV is a unique cannabinoid with compelling therapeutic promise for controlling appetite and treating type 2 diabetes^{1,3}. THCV is a distinctly different molecule from D9-THC and does not have psychotropic properties found in marijuana. It is also legal to possess and sell if derived from hemp.

Cannoid is currently supporting the commercialization of THCV through all phases of finished goods manufacture, including raw material sourcing, formulation, testing, and encapsulation. Our standard THCV softgel is a full spectrum offering containing 5mg of THCV and over 60mg of total cannabinoids buffered in organic hemp seed oil. This blend is available in our smallest softgel, the #4 round, 0.25ml microcap pictured below.

Clinical research tying THCV to appetite suppression goes back to 2009. Reidel, et. al. publishing in the *British Journal of Pharmacology* found: “the phytocannabinoid Delta9-THCV is a novel compound with hypophagic properties and a potential treatment for obesity.”²

More recently in 2020, Abioye and investigators found: “In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients.”¹



(1) Abioye A, Ayodele O, Marinkovic A, Patidar R, Akinwekomi A, Sanyaolu A. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. *J Cannabis Res.* 2020 Jan 31;2(1):6. doi: 10.1186/s42238-020-0016-7. PMID: 33526143; PMCID: PMC7819335.

<https://pubmed.ncbi.nlm.nih.gov/33526143/>

(2) Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. *Br J Pharmacol.* 2009 Apr;156(7):1154-66. doi: 10.1111/j.1476-5381.2008.00107.x. PMID: 19378378; PMCID: PMC2697695.

<https://pubmed.ncbi.nlm.nih.gov/19378378/>

(3) Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. *Diabetes Care.* 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29. PMID: 27573936.

<https://pubmed.ncbi.nlm.nih.gov/27573936/>



303.514.5148
info@cannoid.com
www.cannoid.com




CANNOID

ENCAPSULATION TECHNOLOGIES

CANNABIDIVARIN (CBDV)


CBDV is a powerful, non-psychoactive cannabinoid that has been used to treat chronic stress and anxiety and other concomitant symptoms resulting from limbic system dysfunction. Cannoid is currently supporting studies utilizing CBDV for neuromodulation in cases of severe PTSD, insomnia and social anxiety disorders. Traditional academic researchers are evaluating CBDV as a treatment for neurobehavioral syndromes like Autism Spectrum Disorder ¹ (which has no current pharmacological treatment), and as an anti-epileptic/seizure treatment ².

Cannoid manufactures several softgels that contain significant amounts of CBDV. The highest concentration is found in our 1ml “bunker buster” limbic regulator softgel which has 9.5mg of CBDV in a 375mg total cannabinoid blend.



CANNABINOL (CBN)

Though the clinical literature on CBN is scant, observational studies and customer feedback support its continued use for treating insomnia, stress, and other maladies. Several Cannoid customers are planning CBN sleep studies in 2022. Cannoid’s “Deep Sleep” CBN softgel contains 20mg of CBN with 20mg CBD and 4mg CBDV in our #4 round 0.25ml format.



(1) Pretzsch CM, Floris DL, Voinescu B, Elshahib M, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Pretzsch E, Williams S, Murphy DGM, Daly E, McAlonan GM. Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. *Mol Autism*. 2021 Jul 1;12(1):49. doi: 10.1186/s13229-021-00454-6. PMID: 34210360; PMCID: PMC8252312. <https://pubmed.ncbi.nlm.nih.gov/34210360/>

(2) Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A; GWEP1330 Study Group. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. *Cannabis Cannabinoid Res*. 2021. <https://pubmed.ncbi.nlm.nih.gov/33998885/>



303.514.5148
info@cannoid.com
www.cannoid.com

